Gelclair(R) Placed on Memorial Sloan-Kettering Cancer Center Formulary as Exclusive Product to Treat Patients With Oral

Gelclair(R) Placed on Memorial Sloan-Kettering Cancer Center Formulary as 
Exclusive Product to Treat Patients With Oral Mucositis 
DARA BioSciences Continues to Drive Gelclair Adoption Since Q2 2013
Launch 
RALEIGH, NC  -- (Marketwired) -- 10/17/13 --  DARA BioSciences, Inc.
(NASDAQ: DARA), an oncology supportive care pharmaceutical company
dedicated to providing health care professionals a synergistic
portfolio of medicines to help cancer patients adhere to therapy and
manage side effects arising from cancer treatment, today announced
that Memorial Sloan-Kettering Cancer Center (MSKCC) has placed
Gelclair® on its formulary as the exclusive therapeutic to treat oral
mucositis (OM). Oral mucositis is a painful acute inflammation and
ulceration of the surface of the mouth and throat that commonly
complicates treatment with chemotherapy or local irradiation in
patients with cancer. Without appropriate treatment, OM may lead to
dehydration and malnutrition based on impaired oral intake, both
being serious impediments to overall recovery. 
David J. Drutz, MD, DARA BioSciences' Chief Executive Officer and
Chief Medical Officer, said, "We are excited to work with MSKCC, a
preeminent and internationally renowned cancer treatment institution
with an unmatched tradition and history of providing patients with
exceptional care. MSKCC has chosen to use Gelclair as the exclusive
therapeutic for patients suffering from oral mucositis. As the sole
product on formulary to treat the symptoms of OM, Gelclair will
address this often debilitating side-effect and, importantly, improve
the quality of life for patients at MSKCC in need of therapeutic
intervention."  
MSKCC joins an increasing number of institutions, nationwide, where
Gelclair is currently approved on formulary. "Gaining formulary
acceptance at a cancer treatment center as large and well-respected
as MSKCC is an important overall driver for Gelclair adoption and
success in the marketplace. Since we launched Gelclair only six
months ago, we are confident in our ability to establish Gelclair as
a market leader in short order," concluded Dr. Drutz. 
DARA has exclusive U.S. commercial rights to Gelclair, a uniquely
formulated FDA approved prescription oral gel for treating the
painful symptoms of OM. Gelclair, launched in April 2013, is one of
the three products in DARA's synergistic portfolio of cancer care and
oncology supportive care products. As part of Breast Cancer Awareness
Month, Gelclair, Soltamox® and Bionect® will be featured on The
Balancing Act®; airing on Oct. 14 and 21, 2013 on LifeTime
Television.  
About Oral Mucositis 
Oral Mucositis (OM), characterized by painful acute inflammation and
ulceration of the surface of the mouth and throat in cancer patients,
is caused by chemotherapy and radiation treatment, which disrupts
rapidly dividing epithelial progenitor cells. It is estimated that
approximately 400,000 cases of OM are diagnosed annually. OM can be
an intensely painful condition that often leads to difficulties
swallowing food and fluids, potentially leading to dehydration and
malnutrition. OM can also lead to delays in cancer treatment, through
chemotherapy dose reductions, breaks in radiation treatment,
cessation of cancer therapy, hospitalization and reliance on
parenteral nutrition. Whereas OM is a common complication of
treatment with broadly cytotoxic chemotherapeutic agents or even
targeted cancer drugs, it is particularly severe in patients
receiving radiation therapy for head and neck cancer and in patients
receiving high-dose chemotherapy conditioning prior to hematopoietic
stem cell transplantation. 
About Gelclair (Bioadherent oral rinse gel): 
Gelclair® is an easy-to-use bioadherent oral rinse gel for the
management and relief of pain associated with oral mucositis, a
condition which can occur in cancer patients due to chemotherapy and
radiation treatment. Gelclair has a unique hyaluronic acid-based
formulation and, unlike Mugard™, Episil® and Magic Mouthwash contains
no alcohol, thereby reducing the risk of painful burning and drying.
Gelclair has been broadly studied, demonstrating rapid and effective
relief of pain, improvement in ability to eat and drink and reduction
in the need for rescue analgesics. DARA has exclusive U.S. commercial
rights to Gelclair through a license with The Helsinn Group in
Switzerland. 
For additional information, including a copy of the Full Prescribing
Information, please visit the Gelclair product web site at
www.gelclair.com. 
About DARA BioSciences, Inc. 
DARA BioSciences Inc. is an oncology supportive care pharmaceutical
company dedicated to providing healthcare professionals a synergistic
portfolio of medicines to help cancer patients adhere to their
therapy and manage side effects arising from their cancer treatments. 
DARA holds exclusive U.S. marketing rights to Soltamox (tamoxifen
citrate) oral solution, the only liquid form of tamoxifen, used for
the treatment and prevention of breast cancer. Soltamox offers a
choice to patients who prefer or need a liquid form of tamoxifen.
Gelclair is an alcohol-free bioadherent oral rinse gel for rapid and
effective relief of pain associated with oral mucositis caused by
chemotherapy and radiation treatment. DARA licensed the U.S. rights
to Soltamox from UK-based Rosemont Pharmaceuticals, Ltd., and
Gelclair from the Helsinn Group in Switzerland. Under an agreement
with Innocutis, DARA also markets Bionect (hyaluronic acid sodium
salt, 0.2%) a topical treatment for skin irritation and burns
associated with radiation therapy, in US oncology/radiology markets.  
DARA is focused on expanding its portfolio of oncology supportive
care products in the US, via in-licensing and/or partnering of
complementary late-stage and approved products. In addition, the
company wishes to identify a strategic partner for the clinical
development of KRN5500, currently in Phase 2 for the treatment of
chronic, treatment refractory, chemotherapy induced peripheral
neuropathy (CCIPN). The FDA has designated KRN5500 as a Fast Track
Drug, and DARA is seeking orphan status for the treatment of CCIPN. 
Safe Harbor Statement 
All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements are
subject to factors that could cause actual results to differ
materially for DARA from those projected. Important factors that
could cause actual results to differ materially from the expectations
described in these forward-looking statements are set forth under the
caption "Risk Factors" in DARA's most recent Annual Report on Form
10-K, filed with the SEC on March 28, 2013. Those factors include
risks and uncertainties relating to DARA's ability to timely
commercialize and generate revenues or profits from Bionect®,
Soltamox®, Gelclair® or other products given that DARA only recently
hired its initial sales force and DARA's lack of history as a
revenue-generating company, FDA and other regulatory risks relating
to DARA's ability to market Bionect, Soltamox, Gelclair or other
products in the U.S. or elsewhere, DARA's ability to in-license
and/or partner products, DARA's current cash position and its need to
raise additional capital in order to be able to continue to fund its
operations, the current regulatory environment in which DARA sells
its products, the market acceptance of those products, dependence on
partners, successful performance under collaborative and other
commercial agreements, competition, the strength of DARA's
intellectual property and the intellectual property of others, the
potential delisting of DARA's common stock from the NASDAQ Capital
Market, risks and uncertainties relating to DARA's ability to
successfully integrate Oncogenerix and other risk factors identified
in the documents DARA has filed, or will file, with the Securities
and Exchange Commission ("SEC"). Copies of DARA's filings with the
SEC may be obtained from the SEC Internet site at http://www.sec.gov.
DARA expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in DARA's expectations with
regard thereto or any change in events, conditions, or circumstances
on which any such statements are based. DARA BioSciences and the DARA
logo are trademarks of DARA BioSciences, Inc. 
Image Available: http://www.marketwire.com/library/MwGo/2013/10/16/11
G009155/Images/MultimediaAsset1-1513723144.jpg 
Media Contacts: 
David Connolly or Samantha Stenbeck
LaVoie Group
617-374-8800
dconnolly@lavoiegroup.com
sstenbeck@lavoiegroup.com    
Corporate Contact:
Jenene Thomas
DARA BioSciences
908-938-1475
jthomas@darabio.com  
 
 
Press spacebar to pause and continue. Press esc to stop.